X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (408) 408
index medicus (258) 258
animals (255) 255
staurosporine - pharmacology (230) 230
staurosporine (215) 215
staurosporine - analogs & derivatives (211) 211
apoptosis (183) 183
oncology (148) 148
apoptosis - drug effects (137) 137
staurosporine - therapeutic use (129) 129
mice (121) 121
male (112) 112
pharmacology & pharmacy (109) 109
female (103) 103
antineoplastic agents - therapeutic use (101) 101
cancer (98) 98
enzyme inhibitors - pharmacology (96) 96
cell line, tumor (94) 94
protein kinase c - antagonists & inhibitors (86) 86
research article (83) 83
medicine (81) 81
rats (81) 81
cell biology (77) 77
phosphorylation (77) 77
mutation (74) 74
research (73) 73
antineoplastic agents - pharmacology (71) 71
biochemistry & molecular biology (68) 68
kinases (68) 68
science (67) 67
proteins (66) 66
multidisciplinary sciences (65) 65
protein-kinase-c (64) 64
dose-response relationship, drug (63) 63
expression (63) 63
activation (61) 61
hematology (59) 59
leukemia, myeloid, acute - drug therapy (59) 59
biology (58) 58
cell death (58) 58
signal transduction (58) 58
protein kinase inhibitors - therapeutic use (57) 57
cells, cultured (56) 56
fms-like tyrosine kinase 3 - genetics (52) 52
protein kinase inhibitors - pharmacology (52) 52
cells (51) 51
cell cycle (49) 49
health aspects (48) 48
gene expression (45) 45
chemotherapy (44) 44
protein kinase c (43) 43
staurosporine - administration & dosage (43) 43
cell survival - drug effects (42) 42
antineoplastic combined chemotherapy protocols - therapeutic use (41) 41
enzyme inhibitors - therapeutic use (41) 41
middle aged (41) 41
alkaloids - pharmacology (40) 40
biochemistry (40) 40
cell line (40) 40
leukemia, myeloid, acute - genetics (40) 40
neoplasms - drug therapy (40) 40
leukemia (39) 39
adult (37) 37
blotting, western (37) 37
fms-like tyrosine kinase 3 - antagonists & inhibitors (37) 37
signal transduction - drug effects (37) 37
tumor cells, cultured (37) 37
acute myeloid-leukemia (36) 36
cell proliferation (36) 36
ucn-01 (36) 36
analysis (35) 35
article (35) 35
cell cycle - drug effects (35) 35
inhibition (35) 35
aged (34) 34
cell proliferation - drug effects (34) 34
indoles - pharmacology (34) 34
cytotoxicity (33) 33
death (33) 33
inhibitors (33) 33
physiological aspects (33) 33
protein kinases (33) 33
tumors (33) 33
cell lines (32) 32
immunology (32) 32
time factors (32) 32
apoptosis - physiology (31) 31
in-vitro (31) 31
mitochondria (31) 31
neurosciences (31) 31
neurons - drug effects (30) 30
breast cancer (29) 29
cancer therapies (29) 29
cell survival (29) 29
rodents (29) 29
caspases - metabolism (28) 28
oxidative stress (28) 28
survival (28) 28
tyrosine kinase inhibitor (28) 28
caspase (27) 27
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 03/2011, Volume 117, Issue 12, pp. 3286 - 3293
We examined in vivo FLT3 inhibition in acute myeloid leukemia patients treated with chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly... 
AML | YOUNGER PATIENTS | INTENSIVE CHEMOTHERAPY | SERUM-LEVELS | TYROSINE KINASE INHIBITOR | ACUTE MYELOID-LEUKEMIA | MUTATIONS | HEMATOLOGY | CLINICAL-RESPONSE | APLASTIC-ANEMIA | STEM-CELL MOBILIZATION | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Humans | Staurosporine - analogs & derivatives | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Membrane Proteins - pharmacology | Phenylurea Compounds | Benzenesulfonates - pharmacology | Multicenter Studies as Topic | Protein Kinase Inhibitors - antagonists & inhibitors | Membrane Proteins - physiology | Inhibitory Concentration 50 | Leukemia, Myeloid, Acute - drug therapy | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Membrane Proteins - blood | Pyridines - therapeutic use | Antineoplastic Agents - antagonists & inhibitors | Leukemia, Myeloid, Acute - pathology | Cells, Cultured | Treatment Outcome | Leukemia, Myeloid, Acute - blood | Piperazines - therapeutic use | Piperazines - pharmacology | Randomized Controlled Trials as Topic | Indazoles - pharmacology | Drug Antagonism | Protein Kinase Inhibitors - therapeutic use | Staurosporine - therapeutic use | Carbazoles - therapeutic use | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Carbazoles - pharmacology | Indazoles - therapeutic use | Staurosporine - pharmacology | Clinical Trials and Observations
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 04/2012, Volume 122, Issue 4, pp. 1541 - 1552
Patients with triple-negative breast cancer (TNBC) - defined by lack of estrogen receptor and progesterone receptor expression as well as lack of human... 
SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | P53 MUTATION | CHECKPOINT KINASE-1 | PATHWAY | PROTEIN-KINASE | 7-HYDROXYSTAUROSPORINE UCN-01 | DNA-DAMAGE | S-PHASE | PREDICTIVE-VALUE | CDC25A PHOSPHATASE | Thiophenes - therapeutic use | Apoptosis - drug effects | Humans | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Receptors, Progesterone - genetics | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Camptothecin - administration & dosage | Antineoplastic Agents, Phytogenic - therapeutic use | Camptothecin - analogs & derivatives | Thiophenes - pharmacology | Tumor Suppressor Protein p53 - deficiency | Breast Neoplasms - drug therapy | DNA, Neoplasm - drug effects | Protein Kinase Inhibitors - administration & dosage | Urea - therapeutic use | Mice, Inbred NOD | Mice | DNA Damage | Cell Cycle - drug effects | Genes, cdc | Staurosporine - pharmacology | Urea - pharmacology | Staurosporine - administration & dosage | Neoplasm Proteins - physiology | Staurosporine - analogs & derivatives | Cell Line, Tumor - transplantation | Receptors, Estrogen - analysis | Thiophenes - administration & dosage | Molecular Targeted Therapy | Genes, p53 | Urea - analogs & derivatives | Female | Antineoplastic Agents - pharmacology | Cell Line, Tumor - metabolism | Urea - administration & dosage | Protein Kinases - drug effects | Receptors, Estrogen - genetics | Camptothecin - therapeutic use | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Protein Kinase Inhibitors - therapeutic use | Staurosporine - therapeutic use | Protein Kinases - physiology | Checkpoint Kinase 1 | Neoplasm Proteins - analysis | Protein Kinase Inhibitors - pharmacology | Breast cancer | Genetic aspects | Research | Gene mutations | Health aspects | DNA damage | Estrogen | Càncer de mama | Ratolins (Animals de laboratori) | Apoptosi | Receptors d'hormones | Hormone receptors | Chemotherapy | Mice (Laboratory animals) | Progesterone | Quimioteràpia | Progesterona | Estrògens | Apoptosis
Journal Article
Blood, ISSN 0006-4971, 12/2017, Volume 130, Issue 23, pp. 2469 - 2474
In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and... 
ADULT PATIENTS | TREATMENT-NAIVE | OLDER PATIENTS | INDUCTION CHEMOTHERAPY | LOW-DOSE CYTARABINE | OPEN-LABEL | ACUTE MYELOID-LEUKEMIA | TRANS-RETINOIC ACID | KINASE INHIBITOR | GREATER-THAN-OR-EQUAL-TO-65 YEARS | HEMATOLOGY | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Triazines - therapeutic use | Humans | Leukemia, Myeloid, Acute - metabolism | Staurosporine - analogs & derivatives | Isocitrate Dehydrogenase - antagonists & inhibitors | Molecular Targeted Therapy | fms-Like Tyrosine Kinase 3 - genetics | Aminopyridines - therapeutic use | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Antibodies, Monoclonal, Humanized - pharmacology | Leukemia, Myeloid, Acute - drug therapy | Daunorubicin - administration & dosage | Triazines - pharmacology | Antibodies, Monoclonal, Humanized - therapeutic use | Isocitrate Dehydrogenase - genetics | Treatment Outcome | Clinical Trials as Topic | Sulfonamides - pharmacology | Cytarabine - administration & dosage | Leukemia, Myeloid, Acute - mortality | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Sulfonamides - therapeutic use | Staurosporine - therapeutic use | Aminopyridines - pharmacology | Sialic Acid Binding Ig-like Lectin 3 - antagonists & inhibitors | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Liposomes | Mutation | Aminoglycosides - pharmacology | Staurosporine - pharmacology | Aminoglycosides - therapeutic use | Leukemia, Myeloid, Acute - genetics
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2/2010, Volume 102, Issue 3, pp. 152 - 160
Journal Article
CELLULAR AND MOLECULAR LIFE SCIENCES, ISSN 1420-682X, 11/2017, Volume 74, Issue 22, pp. 4159 - 4169
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 52, Issue 5, pp. 698 - 704
Journal Article
Journal Article
The Lancet, ISSN 0140-6736, 08/2018, Volume 392, Issue 10147, pp. 593 - 606
For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth... 
NEWLY-DIAGNOSED AML | ADULT PATIENTS | MEDICINE, GENERAL & INTERNAL | OLDER PATIENTS | RANDOMIZED PHASE-III | MULTIPARAMETER FLOW-CYTOMETRY | CLONAL HEMATOPOIESIS | RISK MYELODYSPLASTIC SYNDROME | HIGH-DOSE CYTARABINE | STEM-CELL TRANSPLANTATION | MINIMAL RESIDUAL DISEASE | Recurrence | Antibodies, Monoclonal, Humanized - therapeutic use | Risk Assessment | Genomics | Humans | Risk Factors | Hematopoietic Stem Cell Transplantation | Staurosporine - analogs & derivatives | Antineoplastic Agents - therapeutic use | Consolidation Chemotherapy | Remission Induction | Cytarabine - administration & dosage | Patient Selection | Leukemia, Myeloid, Acute - diagnosis | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Staurosporine - therapeutic use | Leukemia, Myeloid, Acute - drug therapy | Leukemia, Myeloid, Acute - therapy | Aminoglycosides - therapeutic use | Leukemia, Myeloid, Acute - genetics | Strategic planning (Business) | Drug approval | Drugs | Pathogenesis | Leukemia | Clinical trials | Cytotoxicity | Genomes | Drug development | Regulatory approval | Older people | Risk assessment | Bone marrow | Drug dosages | Age | Medical research | Hematology | Cloning | Health risks | FDA approval | Patients | Chemotherapy | Medical prognosis | Response rates | Stem cells | Mutation | Risk management | Tumors
Journal Article